In the clinical arena, inhibition of TNFa signaling in otherwise therapy-resistant patients has led to improved treatment outcomes in a variety of immune-mediated diseases, such as RA (10), inflammatory bowel disease (11), adult-onset Still’s disease (12), and psoriasis (13). The gene discussed is TNF; the disease is rheumatoid arthritis.